SCHEMBL12033748

SCHEMBL12033748

c1ccc(-c2ccc(-c3nc(-c4ccc(-c5ccccc5)cc4)nc(-n4c5ccc(-n6c7ccccc7c7cc(-c8ccccc8)ccc76)cc5c5cc(-n6c7ccccc7c7cc(-c8ccccc8)ccc76)ccc54)n3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ RAC2 P15153 1/20 0.39
▸ RAC3 P60763 1/20 0.39
▸ CDC42 P60953 1/20 0.39
▸ RAC1 P63000 1/20 0.39
▸ TSPO P30536 1/20 0.38
▸ PTGER4 P35408 2/20 0.36
▸ NR3C1 P04150 1/20 0.36
▸ NPY5R Q15761 2/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ EDNRB P24530 1/20 0.34
▸ EDNRA P25101 1/20 0.34
▸ DNM1 Q05193 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16689516 1.00 ATM (0.41) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL12033591 1.00 ATM (0.41) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL12033843 1.00 ATM (0.41) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL12033836 1.00 ATM (0.41) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL15371764 0.97 L3MBTL1 (0.46) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL15197830 0.97 L3MBTL1 (0.46) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL11998174 0.97 L3MBTL1 (0.46) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL12093223 0.97 ATM (0.39) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL11998250 0.97 L3MBTL1 (0.46) ATML3MBTL1KDM4ERAC2RAC3
SCHEMBL23085146 0.97 KDM4E (0.41) ATML3MBTL1KDM4ERAC2RAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110309345-A1 COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE HAVING THE SAME E-RAY OPTOELECTRONICS TECHNOLOGY CO., LTD. (TW) 2011-12-22 — — US disclosed
US-20110309345-A1 COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE HAVING THE SAME E-RAY OPTOELECTRONICS TECHNOLOGY CO., LTD. (TW) 2011-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110309345-A1 COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ORGANIC ELECTROLUMINESCENT DEVICE HAVING THE SAME ARL1, MCOLN2, NAT1 ATM 1414/4885L3MBTL1 1396/4885KDM4E 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback